

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Relay Medical Corp. (the "Issuer").

Trading Symbol: RELA

Number of Outstanding Listed Securities: 153,981,912

Date: January 11, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Relay Medical continues to develop and productize multiple products and projects concurrently as well as to consider strategic opportunities that are complimentary to current infrastructure assets. Relay is concurrently developing products within the Fionet Rapid Response Group ("FRR"), the HemoPalm platform and related In Vitro Diagnostics products, Pharmatrac and Osprey Device Networks Corp. (formerly Relay MedNet) as well as the initial development of partially owned subsidiary Glow Lifetech Ltd. In addition the Company continues to support Glow in their Go Public efforts.

Relay and Fio Corporation through their together Fionet Rapid Response Group ("FRR") announced a sales agreement with the U.S. Government, through the U.S. Agency for International Development (USAID), to deploy FRR's Fionet Pandemic Platform to over 100 community-based healthcare sites in Africa. Under the terms of the engagement, the Fionet Platform will be deployed at over 100 community-based healthcare sites, supporting widespread rapid testing, triage and real-time tracking of infectious disease for a contract value of approximately CAD \$330,000. Fionet mobile devices will guide or automate frontline healthcare activity, while continuously capturing and transmitting comprehensive frontline data. Meanwhile, in real time, Fionet Portals enable off-site supervisors to track and direct frontline action, and display real time epidemiological information.

Relay announced a non-brokered private placement financing for gross proceeds of up to \$5,000,000 through the issuance of units in the capital of the Company at a price of \$0.20 per Unit. Each Unit is comprised of: (i) one common share in the capital of the Company; (ii) one Common Share purchase warrant. Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of \$0.30 for a period of eighteen months from the date of issuance. Gross proceeds raised from the Offering will be used for working capital and general corporate purposes. Closing of the Offering is subject to receipt of all necessary corporate and regulatory approvals, including the approval of Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.

2. Provide a general overview and discussion of the activities of management.

Management continued to be involved in the development of its business as more specifically detailed in 1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

See item 1 above.

4. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None in the month of December 2020.

5. Report on any labour disputes and resolutions of those disputes if applicable.

None in the month of December 2020.

6. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None in the month of December 2020.

7. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None in the month of December 2020.

8. Provide details of any securities issued and options or warrants granted.

The Company issued 5,250,000 common shares relating to the conversion election made by the holders of convertible debentures issued in January 2020

The Company issued 65,086 common shares on the exercise of warrants

The Company issued 2,250,000 common shares relating to the exercise of stock options

The Company granted 4,600,000 options to purchase common shares of the Company at a price of \$0.225 and expiring five (5) years from the date of grant, to certain officers, directors, and consultants of the Company.

9. Provide details of any loans to or by Related Persons.

None in the month of December 2020.

10. Provide details of any changes in directors, officers or committee members.

Derek Ivany was appointed to the Strategic Advisory Board. Mr. Ivany will advise Relay on corporate development, mergers, acquisitions, and other strategic initiatives. Having worked with many international groups, Mr. Ivany has established a network of high-profile contacts across such sectors as medicinal products, health and wellness, mining, oil and gas, coffee, technology, horse racing & real- estate. Derek is currently the President of JJ Wolf Investments Ltd., a merchant banking and advisory firm specializing in growth oriented opportunities across all sectors as well as the President of several private companies around the world.

11. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

On March 12, 2020, the World Health Organization ("WHO") declared a global pandemic as a result of the COVID-19 virus. The impacts on global commerce are expected to be far reaching and, at this point, unknown. The global lock-down impacts have negatively impacted the economy as a whole and capital markets in Canada. The effects on the Company's operations have been minor to date but management continues to monitor and contingency plan.

On September 4 2020, Health Canada announced new steps towards gaining control over the COVID-19 pandemic by supporting community-based testing solutions: (1) it will support enhanced solutions for airport testing; (2) it invited potential solutions to be submitted for home testing; and (3) it authorized clinical trials for rapid diagnostics tests ("RDTs") which are fast, inexpensive test strips that can be used in locations outside of laboratories.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated January 11, 2021.

Yoav Raiter

**Name of Director or Senior
Officer**

"Yoav Raiter"
Signature

Chief Executive Officer
Official Capacity

Issuer Details Name of Issuer Relay Medical Corp.	For Month End December 31, 2020	Date of Report YY/MM/D 2021/01/11
Issuer Address 65 International Blvd. Suite 202		
City/Province/Postal Code Toronto, ON M9W 6L9	Issuer Fax No. 1-844-247-6633	Issuer Telephone No. 647-872-9982
Contact Name W. Clark Kent	Contact Position President	Contact Telephone No. 647-872-9982
Contact Email Address ckent@relaymedical.com	Web Site Address https://www.relaymedical.com/	